StreetAlpha.app
Home › Stocks › URGN

UroGen Pharma Ltd. (URGN)

Healthcare
$29.87
▲ +6.30%
LAST CLOSE · NOV 17

UroGen develops and sells gel-based treatments for urinary tract cancers, including Jelmyto and Zusduri. It last closed at $29.87 on Nov 17, up 6.30% on the day. In the past 30 days there were 1 dark pool print totaling $703K, the largest $703K.

AI Auto Pilots
Is URGN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$250.3M
+159.3% vs a year ago
Net income
−$65.8M
−26.3% margin
EPS (diluted)
−$1.31
Free cash flow
−$132.0M
−52.8% margin
Valuation
Market cap
$1.5B
49.0M shares
P/E
–
No P/E while losing money
Price to sales
5.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$85.6M
At Sep 30
Debt
$200.0M
At Sep 30
Shareholder equity
−$125.2M
Shares outstanding
49.0M
At Oct 28
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $48.0M$48.0MFY2021FY2022: $64.4M$64.4MFY2022FY2023: $82.7M$82.7MFY2023FY2024: $90.4M$90.4MFY2024FY2025: $109.8M$109.8MFY2025

From URGN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated URGN in the past 90 days, not enough for a consensus
Average 12-month target
$56.00
▲ 87.5% upside

Based on 1 analyst who set a price target on URGN in the past 90 days. The average target is $56.00, with a high of $56.00 and a low of $56.00, compared with the last close of $29.87.

Low $56.00Avg $56.00High $56.00
Blue marker: last close $29.87
Highest target$56.00
Average target$56.00
Lowest target$56.00
Latest rating changes
GuggenheimMaintained
Nov 5Buy$56
GuggenheimMaintained
Aug 6Buy$58
HC Wainwright & Co.Maintained
Aug 6Buy$75
TD CowenMaintained
Aug 5Buy$60
GuggenheimMaintained
Jul 21Buy$42
DateFirmActionRatingPrice target
Nov 5GuggenheimMaintainedBuy$56
Aug 6GuggenheimMaintainedBuy$58
Aug 6HC Wainwright & Co.MaintainedBuy$75
Aug 5TD CowenMaintainedBuy$60
Jul 21GuggenheimMaintainedBuy$42
Loading…

Technical Analysis

URGN · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 2% below its 20 day and 22% below its 50 day average. It is 6% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 44). The nearest support is the Pivot at $28.95, and the nearest resistance the 20 day average at $30.46.

Short trendBearish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityHigh, 7.9%/day
Key levels
$50.8152 week high+70.1%
$39.62100 day average+32.6%
$36.4050 day average+21.9%
$31.78200 day average+6.4%
$30.82Pivot R1+3.2%
$30.69Swing high (May 27)+2.7%
$30.4620 day average+2.0%
$29.87Last close
$28.95Pivot−3.1%
$28.00Pivot S1−6.3%
$26.00Swing low (Jun 1)−13.0%
$16.5052 week low−44.8%
Indicators
RSI (14)44.49Middle of its rangeNeutral
MACD-2.79Above its signal lineBullish
Stochastic38.4Middle of its rangeNeutral
ADX (14)41.5Strong downtrend
Williams %R-43.3Oversold below −80, overbought above −20Neutral
CCI (20)-27.2Oversold below −100, overbought above 100Neutral
Rate of change−13.2%Change over 10 sessionsBearish
ATR (14)$2.35Typical daily range, 7.8% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for URGN

What happened before

See how URGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow URGN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How URGN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in URGN in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$703K
Largest print
$703K
Loading…

URGN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲127 buying vs 61 selling
  • ▼Held by funds -3.8 pts
  • ▲Funds holding +30
  • ▼Superinvestors: 2 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding219189+15.9%
In funds' top 1076+16.7%
Held by funds82.7%86.5%−3.8 pts
New / increased49 / 7839 / 61+27.0%
Reduced / sold out45 / 1654 / 21−18.7%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See URGN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether URGN is in one of them and how their past URGN trades turned out.

URGN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered URGN in an article yet. Here's the latest on the wider market.

About UroGen Pharma

UroGen is a biotechnology company based in Ra'Anana, Israel, that develops and sells treatments for urothelial cancers, which affect the lining of the urinary tract. Its products use a gel technology called RTGel, which turns from liquid to gel at body temperature so that a cancer drug can stay in the bladder or upper urinary tract for longer. Its approved products, Jelmyto and Zusduri, both contain the chemotherapy drug mitomycin, and the company is also developing an investigational oncolytic virus. Its customers are patients with these cancers and the doctors who treat them.

Headquarters
Ra'Anana, Israel